JNJ

Johnson & Johnson’s COVID-19 Vaccine Gets the Green Light

by

Image Shown: We include Johnson & Johnson as an idea in both the Best Ideas Newsletter and Dividend Growth Newsletter portfolios. The health care giant is home to over two dozen ‘platforms/products’ that generate $1.0+ billion in annual sales, as you can see in the above graphic. Recently, Johnson & Johnson’s COVID-19 vaccine received emergency use authorization from the US CDC, which will provide public health authorities with another arrow in their quiver as it relates to bringing an end to the public health crisis. Image Source: Johnson & Johnson – Fourth Quarter of 2020 IR Earnings Presentation By Callum Turcan At the end of February 2021, the US Centers for Disease Control and Prevention (‘CDC’) gave emergency use authorization … Read more

Johnson & Johnson’s COVID-19 Vaccine Candidate Nears the Finish Line

by

Image Source: Johnson & Johnson – Fourth Quarter of Fiscal 2020 IR Earnings Presentation By Callum Turcan Over the past several months, shares of Johnson & Johnson (JNJ) have steadily climbed higher as investors are warming up to its improving outlook and strong financial position. In April 2020, Johnson & Johnson increased its quarterly per share dividend by over 6% sequentially, highlighting its commitment to income seeking investors. Johnson & Johnson is actively working towards developing a safe and viable vaccine to help put an end to the ongoing coronavirus (‘COVID-19’) pandemic. Recent updates indicate the firm’s COVID-19 vaccine candidate is near the finish line. We include Johnson & Johnson in both the Best Ideas Newsletter and Dividend Growth Newsletter … Read more

Three Newsletter Portfolio Ideas Post Stellar Earnings Updates: JNJ, LMT, MSFT

by

Image Source: Johnson & Johnson – Fourth Quarter of Fiscal 2020 Earnings IR Presentation By Callum Turcan In alphabetic order by ticker: JNJ, LMT, MSFT Three of the newsletter portfolio ideas recently reported stellar earnings updates and provided promising outlooks that we want to draw to our members’ attention. With global health authorities working towards putting an end to the coronavirus (‘COVID-19’) pandemic, aided by ongoing vaccine distribution efforts, the outlook for the global economy is bright and getting brighter. Johnson & Johnson (JNJ) We include healthcare conglomerate Johnson & Johnson (JNJ) in both the Best Ideas Newsletter and Dividend Growth Newsletter portfolios. Shares of the company have been on a steep upward climb since early November 2020 as investors … Read more

ALERT: Raising Cash in the Newsletter Portfolios

by

January 27, 2021 ALERT: Raising Cash in the Newsletter Portfolios We are raising the cash position in the simulated Best Ideas Newsletter portfolio and simulated Dividend Growth Newsletter portfolio to 10%-20%. — By Brian Nelson, CFA — Our research has been absolutely fantastic for a long time, but 2020 may have been our best year yet. You can read the 2020 recap here. With the S&P 500 trading within our fair value estimate range of 3,530-3,920 (and the markets rolling over while showing signs of abnormal behavior), we’re raising the cash position in the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio to 10%-20%. — For more conservative investors, the high end of this range may even be larger, especially … Read more

Steris Ties the Knot with Cantel Medical

by

Image Shown: Cantel Medical Corp is getting bought out by Steris PLC through a cash-and-stock deal. The image up above highlights Cantel Medical’s promising long-term growth outlook, though its performance in 2020 was subdued due to headwinds created by the coronavirus (‘COVID-19’) pandemic. In our view, Steris was attracted to Cantel Medical’s improving outlook (the latter started to stage an impressive rebound in the second half of calendar year 2020) and the ability for the combined firm to generate substantial synergies. Image Source: Cantel Medical Corp – December 2020 IR Presentation By Callum Turcan On December 2, we highlighted (link here) the ongoing turnaround at Cantel Medical Corp (CMD) and noted that “we (thought) Cantel Medical is one for the … Read more

All I Want for Christmas Are Dividend Aristocrats

by

Image Source: Five Furlongs It may not be as catchy as Mariah Carey’s Christmas hit, “All I Want For Christmas Is You,” but if you ask a dividend growth investor what they might want for Christmas as it relates to an investment, they might start singing about a long list of Dividend Aristocrats–a list of companies that have increased their dividends in each of the past 20-25+ years. Therefore, we wanted to do something special this Christmas for members. We’ve aggregated a list of every non-financial Dividend Aristocrat in our 16-page stock report coverage universe and made a list conveniently available below, including some key data and links directly to their 16-page stock reports (pdf). To access the 16-page stock … Read more

Walking Through the Calculation of the Dividend Cushion Ratio

by

A cow for her milk, A hen for her eggs, And a stock, by heck, For her dividends. An orchard for fruit, Bees for their honey, And stocks, besides, For their dividends. – John Burr Williams, “The Theory of Investment Value” (1938) Executive Summary: We believe the Dividend Cushion ratio is one of the most helpful tools an income or dividend growth investor can use in conjunction with qualitative dividend analysis. The ratio is one-of-a-kind in that it is both free-cash-flow based, considers balance sheet health, and is forward looking. Since its development in 2012, we estimate its efficacy at ~90% in helping to forewarn readers of impending dividend cuts. For companies where Valuentum reports are available, the Dividend Cushion ratio can be found in a stock’s Dividend … Read more

Pfizer/BioNTech Vaccine Not a Catalyst for Portfolio Changes

by

Image: BioNTech. Next Generation Immunotherapy Presentation, October 2020. By Brian Nelson, CFA The world received great news this week that the days of this terrible COVID-19 pandemic may finally be numbered. On November 9, Pfizer (PFE) and BioNTech (BNTX) announced that “their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.” Here is what Pfizer’s CEO Albert Bourla had to add with respect to the development: Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19. We are reaching this critical milestone in our vaccine development … Read more

Best Ideas Newsletter Portfolio Holdings Are Surging!

by

Image: The holdings in the Best Ideas Newsletter during the trading session November 4. We continue to pound the table on our best ideas. By Brian Nelson, CFA If you were like me, you stayed up as long as you could last night watching the U.S. election coverage before it became too difficult to keep your eyes open. When I went to sleep, it seemed as though Donald Trump would be re-elected. The only state that appeared to flip to the Democrats from the 2016 election was Arizona, meaning Trump would still retain greater than the 270 electoral votes required to gain re-election. Well, that was last night, and this is today. As more and more votes came in last … Read more